Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 83Neoplasms 79Colorectal Neoplasms 68Neoplasm Metastasis 66Prostatic Neoplasms 62Leukemia, Myeloid, Acute 61Ovarian Neoplasms 58Recurrence 56Pancreatic Neoplasms 56Multiple Myeloma 52Melanoma 41Lung Neoplasms 38Glioblastoma 38Triple Negative Breast Neoplasms 36Squamous Cell Carcinoma of Head and Neck 35Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Myelodysplastic Syndromes 26Carcinoma, Hepatocellular 26Lymphoma, B-Cell 25Advanced Solid Tumor 25Sarcoma 24Leukemia, Lymphocytic, Chronic, B-Cell 24

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × 90 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡